TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12562448

Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet, 15 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet, 30 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intact capsule formulation of lansoprazole
Number of subjects: 120
Study: 11253476

Group type: EXPERIMENTAL
Intervention: Acoustic speech analysis in ALS patients
Number of subjects: 77
Study: 8637408

Group type: EXPERIMENTAL
Intervention: Velnacrine (30, 75, 150, 225 mg/day for one week)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Velnacrine
Number of subjects: 236
Study: 1350927

Group type: EXPERIMENTAL
Intervention: Acetorphan (100 mg t.d.s.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6529914

Group type: EXPERIMENTAL
Intervention: 250 mg Ro 21-5521 per day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30904178

Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine 80/10 mg + Rosuvastatin 20 mg (TAR group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine 80/10 mg (TA group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + Rosuvastatin 20 mg (TR group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (TA and TR)
Number of subjects: 134
Study: 29774562

Group type: EXPERIMENTAL
Intervention: Simple, low-cost group-counselling programme
Number of subjects: 769

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 769
Study: 27094109

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study: 24184810

Group type: EXPERIMENTAL
Intervention: Simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo plus PegIFN and RBV for 48 weeks
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Simeprevir (100 or 150 mg, once daily)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 22266898

Group type: EXPERIMENTAL
Intervention: 15 mL mepivacaine 1.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: 40 mL mepivacaine 1.5%
Number of subjects: 30
Study: 21148134

Group type: EXPERIMENTAL
Intervention: Weight lifting intervention (gym membership and 13 weeks of supervised instruction, followed by 9 months unsupervised)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Weight lifting intervention (among women with 5 or more lymph nodes removed)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (among women with 5 or more lymph nodes removed)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Weight lifting intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study: 17937368

Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 12656547

Group type: EXPERIMENTAL
Intervention: In-line catheter suction system
Number of subjects: 14

Group type: COMPARATOR
Intervention: Open catheter suction
Number of subjects: 14
Study: 10901509

Group type: COMPARATOR
Intervention: Simvastatin (20 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hormone replacement therapy (0.625 mg conjugated oestrogen and 2.5 mg medroxyprogesterone acetate daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combination therapy (simvastatin + hormone replacement therapy)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16
Study: 8622055

Group type: EXPERIMENTAL
Intervention: Alternating regimen (one cycle of MOPP monthly alternated with one cycle of ABVD)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Hybrid regimen (one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Alternating regimen
Number of subjects: 427

Group type: COMPARATOR
Intervention: Hybrid regimen
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 427
Study: 1358118

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study: 6367362

Group type: EXPERIMENTAL
Intervention: Sulpiride (800-2800 mg/day, median 1600 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Haloperidol (6-18 mg/day, median 12 mg/day)
Number of subjects: 16
Study: 31465088

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus aflibercept (4 mg/kg every 2 weeks for 6 cycles, 3 months)
Number of subjects: 180

Group type: COMPARATOR
Intervention: mFOLFOX6 without aflibercept
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus aflibercept
Number of subjects: 180
Study: 28573377

Group type: EXPERIMENTAL
Intervention: Tailored patient activation DXA result letter and bone health brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care (no tailored letter or brochure)
Number of subjects: 7749
Study: 25788199

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) for 5 years
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) for 5 years in HBeAg-positive patients
Number of subjects: 348
Study: 23122916

Group type: EXPERIMENTAL
Intervention: LOW (0.25 mA current, 130 μs pulse width)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: MEDIUM (0.5-1.0 mA, 250 μs)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: HIGH (1.25-1.5 mA, 250 μs)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: VNS therapy (all doses)
Number of subjects: 331
Study: 22194125

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 54

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 54
Study: 19351753

Group type: EXPERIMENTAL
Intervention: G3139
Number of subjects: 0
Study: 17097772

Group type: EXPERIMENTAL
Intervention: Prednisone + Phenylbutyrate
Number of subjects: 7
Study: 17595600

Group type: EXPERIMENTAL
Intervention: Walking recovery rehabilitation program with specific back exercises
Number of subjects: 37

Group type: COMPARATOR
Intervention: Walking recovery rehabilitation program without specific back exercises (control group)
Number of subjects: 37
Study: 11450082

Group type: EXPERIMENTAL
Intervention: Surgery for spontaneous supratentorial intracerebral haemorrhage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 0
Study: 8783326

Group type: EXPERIMENTAL
Intervention: Intra-articular clonidine 150 micrograms diluted in 20 ml of isotonic saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Morphine 1 mg diluted in 20 ml of isotonic saline injected into the knee joint
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intra-articular isotonic saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intra-articular isotonic saline and subcutaneous clonidine 150 micrograms
Number of subjects: 40
Study: 1740587

Group type: EXPERIMENTAL
Intervention: Muscarinic stimulation by methacholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylephrine (alpha-adrenergic agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic agonists
Number of subjects: 0
Study: 6711670

Group type: EXPERIMENTAL
Intervention: Dichotic listening test using consonant‐vowel dichotic stimuli
Number of subjects: 90
Study: 30678199

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1200 IU vitamin D₃ per day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 29920116

Group type: EXPERIMENTAL
Intervention: molindone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 119
Study: 27127102

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine (Val/Aml 80/5 mg) single-pill combination for 8 weeks
Number of subjects: 11312
Study: 25458200

Group type: EXPERIMENTAL
Intervention: Erythromycin (400 mg, twice daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 22904136

Group type: EXPERIMENTAL
Intervention: Prevalent CIN 3 cases diagnosed within 2 years
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Incident CIN 3 cases diagnosed following an incident HPV infection
Number of subjects: 613
Study: 20399059

Group type: EXPERIMENTAL
Intervention: Niacin (target dose, 2000 mg/day)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 315
Study: 18700693

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 15800995

Group type: EXPERIMENTAL
Intervention: HBV pre-core mutant group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HBV pre-core wild-type group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 140
Study: 12876093

Group type: COMPARATOR
Intervention: Diet very low in saturated fat (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lovastatin, 20 mg/d
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diet high in plant sterols, soy protein, viscous fibers, and almonds (dietary portfolio)
Number of subjects: 46
Study: 10447643

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3% eye drops twice daily (LF)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control antibiotics (combined control group, CCG)
Number of subjects: 582
Study: 8681494

Group type: EXPERIMENTAL
Intervention: Quinaprilat (0.5 to 1.0 mg, 1.0 to 2.5 mg, 5.0 to 10.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinaprilat (multiple doses every 6 hours on days 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2071560

Group type: EXPERIMENTAL
Intervention: Oral physostigmine administered four times daily for 3 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31776012

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Selective local anaesthetic (SNT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (Corticosteroids)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 31862738

Group type: EXPERIMENTAL
Intervention: HH intervention including interactive simulation learning, educational emails, and education and poster reminders from WHO and Global Handwashing Day website.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 70
Study: 27806997

Group type: EXPERIMENTAL
Intervention: BokSmart Safe Six exercise intervention in warm-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual warm-up)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BokSmart Safe Six exercise intervention
Number of subjects: 0
Study: 26138292

Group type: EXPERIMENTAL
Intervention: Enforced expression of Bcl-3 in CD4+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bcl-3 silencing in CD4+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bcl-3 levels in CD4+ T cells from RA patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 induction of Bcl-3 expression in CD4+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptome analysis of Bcl-3-transduced CD4+ T cells
Number of subjects: 0
Study: 24476350

Group type: EXPERIMENTAL
Intervention: Sexual risk-reduction intervention
Number of subjects: 738

Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 738
Study: 21846536

Group type: EXPERIMENTAL
Intervention: Root ZX II in AP group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Root ZX II in VT group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison between AP and VT groups
Number of subjects: 27
Study: 20307823

Group type: EXPERIMENTAL
Intervention: Individualized yoga plus standard care
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard care (No Yoga)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Individualized yoga treatment
Number of subjects: 54
Study: 17991119

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (gonadotrophins)
Number of subjects: 33
Study: 14768920

Group type: EXPERIMENTAL
Intervention: Ultrasound online imaging during epidural puncture
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasound offline scan technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional combined spinal‐epidural anaesthesia (Control)
Number of subjects: 30
Study: 12153648

Group type: EXPERIMENTAL
Intervention: Birth center care
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1063
Study: 11475743

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Potassium magnesium aspartate
Number of subjects: 16
Study: 7647944

Group type: COMPARATOR
Intervention: Educational paragraph describing CPR and its outcomes (read to half of respondents)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Knowledge of or experience with Alzheimer's disease
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Greater income
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 661
Study: 2475915

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Laser + high-dose-rate Iridium 192 afterloading therapy
Number of subjects: 37
Study: 1031798

Group type: EXPERIMENTAL
Intervention: Insulin injection tests (HOLLANDER criterion)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Insulin injection tests (BACHRACH criterion)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sodium chloride test
Number of subjects: 74
Study: 30877216

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + csDMARD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + csDMARD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + csDMARD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (ADA) 40 mg
Number of subjects: 0
Study: 28727704

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with dexamethasone 8 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% with saline (control)
Number of subjects: 82
Study: 25954828

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Laser plus acidulated phosphate fluoride (APF)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (negative control)
Number of subjects: 186
Study: 23450028

Group type: EXPERIMENTAL
Intervention: Unipedicular balloon kyphoplasty
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bipedicular balloon kyphoplasty
Number of subjects: 44
Study: 21320829

Group type: EXPERIMENTAL
Intervention: Web-based neuroanatomical localization application
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard textbook resources (control group)
Number of subjects: 39
Study: 19850252

Group type: EXPERIMENTAL
Intervention: Primary PCI with Proxis Embolic Protection System
Number of subjects: 284

Group type: COMPARATOR
Intervention: Primary PCI alone (Control)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 284
Study: 16840382

Group type: EXPERIMENTAL
Intervention: Specialist nurse follow-up
Number of subjects: 154

Group type: COMPARATOR
Intervention: Respiratory doctor follow-up
Number of subjects: 154
Study: 14509552

Group type: EXPERIMENTAL
Intervention: Non-antibiotic prescriptions (co-prescriptions)
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Antibiotic prescriptions
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Mucomodifiers, steroidal anti-inflammatory drugs, and bronchodilators
Number of subjects: 5469

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs and antitussives
Number of subjects: 5469
Study: 10839226

Group type: EXPERIMENTAL
Intervention: Thigh protectors
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no thigh protectors)
Number of subjects: 2
Study: 9177364

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36
Study: 8463521

Group type: EXPERIMENTAL
Intervention: L-deprenyl
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3544661

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (MH) prophylaxis, 1 g three times daily
Number of subjects: 109

Group type: COMPARATOR
Intervention: No MH prophylaxis
Number of subjects: 109
Study: 29864418

Group type: EXPERIMENTAL
Intervention: Audiovisual sexual stimuli (AVSS) during the follicular phase
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Audiovisual sexual stimuli (AVSS) during the luteal phase
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: First exposure to AVSS during luteal phase
Number of subjects: 22
Study: 29873467

Group type: EXPERIMENTAL
Intervention: LMA Proseal™ (LMA-P)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: LMA Supreme™ (LMA-S)
Number of subjects: 180
Study: 23989910

Group type: EXPERIMENTAL
Intervention: Single intravenous injection of flomoxef (group 1)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Multiple doses of flomoxef (five additional doses after surgery, group 2)
Number of subjects: 279
Study: 21957982

Group type: EXPERIMENTAL
Intervention: Penile block (0.25% bupivacaine, 0.5 mg·kg(‐1))
Number of subjects: 54

Group type: COMPARATOR
Intervention: Caudal epidural (0.25% bupivacaine, 0.5 ml·kg(‐1))
Number of subjects: 54
Study: 20049951

Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine (6-MP) at 30 mg/day for 12 weeks
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 6-MP at 15-80 mg/day based on RBC 6-TGN, WBC count, and body weight
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Regular measurement of RBC 6-TGN
Number of subjects: 257
Study: 18720362

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 375
Study: 16253102

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bioabsorbable membrane
Number of subjects: 32
Study: 12381079

Group type: EXPERIMENTAL
Intervention: ACEIs (captopril and enalapril)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 119
Study: 10195551

Group type: EXPERIMENTAL
Intervention: Sevoflurane and N2O from a rebreathing bag (Sevo/Bag)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% and N2O 60% from a circle system (Sevo/Circle)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg/kg as an i.v. bolus
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thiopental sodium 5 mg/kg as an i.v. bolus
Number of subjects: 80
Study: 8665995

Group type: EXPERIMENTAL
Intervention: Flosulide 25 mg b.d.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flosulide (both doses)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flosulide (repeated treatment)
Number of subjects: 8
Study: 1983629

Group type: EXPERIMENTAL
Intervention: Multivariate statistical methods applied to clinical databank or registry data
Number of subjects: 0
Study: 7437274

Group type: EXPERIMENTAL
Intervention: Intravenous lysine salicylate 1.8 g (corresponding to acetylsalicylic acid (ASA) 1.0 g)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dipyrone 1.0 g
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous lysine salicylate (ASA)
Number of subjects: 17
Study: 30758170

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise on sea sand (SS group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Self-management (SM group)
Number of subjects: 22
Study: 30223235

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (n=46)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sensorimotor with passive interventions (n=48)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Active self-exercise (Control group, n=46)
Number of subjects: 140
Study: 26626794

Group type: EXPERIMENTAL
Intervention: Repeated vaginal dinoprostone (group A, n = 47)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous oxytocin (group B, n = 47)
Number of subjects: 94
Study: 24105610

Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg twice daily for 4 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 25
Study: 21831254

Group type: EXPERIMENTAL
Intervention: Mouth rinse and dentifrice with 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control regimen (minus active ingredients dentifrice and mouth rinse)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 0
Study: 20577130

Group type: EXPERIMENTAL
Intervention: CPAP added to conventional treatment (n = 38)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CPAP > 5.8 h
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CPAP group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional treatment alone (n = 37)
Number of subjects: 96
Study: 17434094

Group type: EXPERIMENTAL
Intervention: Glucose-potassium-insulin (GKI) infusions
Number of subjects: 933

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 933
Study: 16315822

Group type: EXPERIMENTAL
Intervention: Protected carotid artery stenting (PCAS)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1